Cost-effectiveness models:

Health Economic Modelling

Quantified economic evidence can significantly aid a product’s value story. Medialis are perfectly positioned, can advise on the choice, as well as execute preparation of the optimal tool.

We ensure the highest standards and compliance with the latest guidelines.

Our portfolio includes:

  • cost-effectiveness

  • cost-utility

  • budget impact

  • and other types of economic modelling.

 

Following the guidelines given by the EU commission in 2001:

Relative effectiveness

The concept of relative effectiveness is an increasing feature of Member State evaluation of health technologies. The development of new medicines and other technologies that provide additional therapeutic benefits will contribute to maintaining progress in improving the quality and effectiveness of health care. The Commission's objective is to provide a forum for Member States, who wish to use relative effectiveness measures, to share ideas on how they may be operated effectively, quickly and placing the minimum burden on the parties involved.

Relative effectiveness, as applied to health care technologies such as medicines, has two components: the added therapeutic value (ATV) of a medicine (its clinical effectiveness compared to other treatments), and its cost-effectiveness, which builds on ATV and brings cost considerations into the comparison. Cost-effectiveness considerations are being increasingly brought into pharmaceutical pricing and reimbursement decisions by competent authorities. Particularly as the continuous incorporation of new health technologies into health care systems is an important driver of rising health care costs. ATV considerations are of interest to a wider group of health stakeholders including health professionals and patients, as well as competent authorities. It is important that this information is effectively communicated to them.

In terms of pricing and reimbursement decisions, there are a variety of compulsory and voluntary systems in Member States which provide a mechanism for allocating limited resources that take account of relative effectiveness, in particular, cost-effectiveness, issues. The Commission wants to see that such schemes operate as smoothly as possible and, in particular, that patients have quick access to important new medicines. The Commission has specific responsibility for ensuring the Transparency Directive (Council Directive 89/105/EEC) is implemented correctly. The application of relative effectiveness criteria in member states has a direct impact on prices and reimbursement. While the Commission recognises that pricing and reimbursement decisions are the responsibility of each Member State, there is a clear common interest in generating and sharing information in order to increase the transparency and effectiveness of relative effectiveness procedures

It is the Commission's view that the authorisation process for medicines must continue to focus on the key public health criteria of safety, quality, and efficacy. The issue of relative effectiveness, while important, should be kept entirely separate from this process as it is most useful once the medicines are on the market and being used alongside existing therapeutic options.

https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52003DC0383

 

Tweet